Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) just unveiled an update.
JW Therapeutics has submitted Phase I study data of Relmacabtagene autoleucel injection for treating active systemic lupus erythematosus (SLE) in Chinese adults to the National Medical Products Administration of China. The study demonstrated significant efficacy and a favorable safety profile for Relma-cel, with all 12 patients achieving SRI-4 remission and drug-free status, highlighting its potential as a new treatment option for SLE, a condition with significant unmet medical needs in China.
The most recent analyst rating on (HK:2126) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is an independent and innovative biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products.
Average Trading Volume: 4,594,402
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.57B
For detailed information about 2126 stock, go to TipRanks’ Stock Analysis page.